Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

99.11 +1.80 (+1.85%)
Streaming Delayed Price Updated: 9:53 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
24 25 Next >
News headline image
Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
From Incyte
Via Business Wire
News headline image
7 Biotech Stocks That Could Cure Your Portfolio Woes ↗
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
From Incyte and MorphoSys U.S. Inc.
Via Business Wire
News headline image
Ominous Death Cross Forms On Incyte's Chart ↗
 
Via Benzinga
News headline image
What 13 Analyst Ratings Have To Say About Incyte ↗
 
Via Benzinga
News headline image
The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech ↗
One executive called this the most "damaging" decision in five decades. 
Via Investor's Business Daily
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
News headline image
S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday ↗
Micron and Charles Schwab were among the top performers. 
Via Investor's Business Daily
News headline image
Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target ↗
Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023 ↗
 
Via Benzinga
News headline image
Incyte Stock Dives On Surprise Rejection For Updated Jakafi ↗
The company had hoped to gain approval for an extended-release version of its biggest drug. 
Via Investor's Business Daily
News headline image
Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday ↗
Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to... 
Via Benzinga
News headline image
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
From Incyte
Via Business Wire
News headline image
Second Setback For Incyte's LIMBER Program - Analyst Says 'Resolution Timelines Unclear To Assess Impact' ↗
 
Via Benzinga
News headline image
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
From Incyte
Via Business Wire
News headline image
Analyst Expectations for Incyte's Future ↗
 
Via Benzinga
News headline image
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗
 
Via Benzinga
News headline image
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
From Incyte
Via Business Wire
News headline image
7 Healthcare Stocks to Buy for Long-Term Growth and Stability ↗
These healthcare stocks to buy offer spectacular upside potential ahead in your defensive portfolio as we get deeper into 2023. 
Via InvestorPlace
News headline image
Incyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte Corporation
Via Business Wire
News headline image
Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo
From Incyte Corporation
Via Business Wire
News headline image
Why Shares of MacroGenics Climbed Thursday ↗
The cancer-focused biotech delivered a strong earnings report. 
Via The Motley Fool
News headline image
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
From Incyte Corporation
Via Business Wire
News headline image
Which S&P 500 Stocks Look Most Attractive Now? ↗
Using ValuEngine’s advanced screening tool, we select 4- and 5-rated stocks in the SPY ETF. As we can see in the table below, 20 stocks passed the screen with two strong buys; CEG and NCLH. 
Via Talk Markets
News headline image
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte Discontinues LIMBER-304 On Doubts Regarding Meeting Primary Goal, Analyst Says It Underpins Some Investor Concerns ↗
 
Via Benzinga
News headline image
Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
From Incyte
Via Business Wire
News headline image
Incyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and Adolescents
From Incyte Corporation
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.